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Vaikuttaa siltä, että monet keliaakikot kärsivät pitkittyneistä vatsavaivoista ja huonontuneesta 
elämänlaadusta tiukasta gluteenittomasta ruokavaliosta huolimatta. Tutkimuksessamme ”Persistent 
symptoms and reduced quality of life in treated coeliac disease patiets: a large cross-sectional 
study” pyrimme löytämään ennustavia tekijöitä edellä mainittuihin ongelmiin. 
Koko maan kattavassa poikkileikkaustutkimuksessa 596 aikuista keliaakikkoa täyttivät 
suostumuslomakkeet ja strukturoidut kyselylomakkeet, jonka jälkeen heitä haastateltiin. 
Osallistujilta kysyttiin demografisia tietoja, heidän tautinsa kliinistä kuvaa, hoitoa, diagnoosiaikaa 
ja -paikkaa sekä keliakiaan liittyviä tai muita mahdollisia sairauksia. Terveyteen liittyvän 
elämänlaadun ja ruoansulatuskanavan oireiden arviointiin käytettiin validoituja, 
keliakiatutkimuksessa laajalti käytettyjä kyselylomakkeita. Pitäytymistä gluteenittomassa 
ruokavaliossa arvioitiin potilaan oman ilmoituksen sekä serologisten testien perusteella. Tuloksien 
analysointiin käytettiin binaarista logistista regressiota, jonka avulla laskettiin ristitulosuhteet (OR) 
sekä 95 % luottamusvälit.  
Diagnoosin saaminen työikäisenä sekä merkittävät tai pitkään jatkuneet oireet diagnoosihetkellä 
altistivat pitkittyneille, nykyhetkenä esiintyville oireille. Sen sijaan osallistujilla, jotka kärsivät 
diagnoosihetkellä suoliston ulkopuolisista oireista, oli vähemmän pitkittyneitä ruoansulatuskanavan 
oireita. Lisäksi kilpirauhassairaus, keliakiaan liittymättömät ruoka-aineintoleranssit, 
ruoansulatuskanavan sairaudet sekä mikä tahansa keliakiaan liittyvä liitännäissairaus altistivat 
pitkittyneille vatsavaivoille. Pitkä oireiden kesto ennen diagnoosin saamista sekä psykiatriset 
sairaudet altistivat huonontuneelle elämänlaadulle. 
Tutkimus osoitti, että merkittävä osa keliaakikoista kärsii pitkittyneistä vatsaoireista ja 
huonontuneesta elämänlaadusta tarkkaan noudatetusta ruokavaliosta huolimatta. Tutkimuksen 
tulokset tähdentävät keliakian varhainen toteamisen ja huolellisen hoidon tärkeyttä. 
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Abstract 
Background 
Evidence suggests that many coeliac disease patients suffer from persistent clinical symptoms and 
reduced health-related quality of life despite a strict gluten-free diet. We aimed to find predictors for 
these continuous health concerns in long-term treated adult coeliac patients. 
Methods 
In a nationwide study, 596 patients filled validated Gastrointestinal Symptom Rating Scale and 
Psychological General Well-Being questionnaires and were interviewed regarding demographic 
data, clinical presentation and treatment of coeliac disease, time and place of diagnosis and presence 
of coeliac disease-associated or other co-morbidities. Dietary adherence was assessed by a 
combination of self-reported adherence and serological tests. Odds ratios and 95% confidence 
intervals were calculated by binary logistic regression.    
Results 
Diagnosis at working age, long duration and severity of symptoms before diagnosis and presence of 
thyroidal disease, non-coeliac food intolerance or gastrointestinal co-morbidity increased the risk of 
persistent symptoms. Patients with extraintestinal presentation at diagnosis had fewer current 
symptoms than subjects with gastrointestinal manifestations. Impaired quality of life was seen in 
patients with long duration of symptoms before diagnosis and in those with psychiatric, neurologic 
or gastrointestinal co-morbidities. Patients with persistent symptoms were more likely to have 
reduced quality of life. 
Conclusions 
There were a variety of factors predisposing to increased symptoms and impaired quality of life in 
coeliac disease. Based on our results, early diagnosis of the condition and consideration of co-
morbidities may help in resolving long-lasting health problems in coeliac disease. 
 
Keywords: Coeliac disease, Symptoms, Quality of life, Gluten-free diet, Adults 
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Background  
At present, the only treatment for coeliac disease is a lifelong gluten-free diet, i.e. exclusion of 
wheat-, rye- and barley-containing cereals and food products. Upon removal of gluten from the diet 
clinical symptoms are usually rapidly alleviated, while recovery of the duodenal mucosa may take 
several months or even years (1). The treatment may also prevent many coeliac disease-associated 
complications such as intestinal malignancies (2). Notwithstanding these benefits, the stigma of a 
chronic disorder and the need for major dietary restrictions increases the self-perceived burden of 
illness and may impair patients’ quality of life (3,4). The symptoms may also remain despite a long-
term and strict diet (5,6). As a result, in some studies even well-treated coeliac patients have failed 
to attain well-being similar to that of the population in general (7,8), albeit that there are also 
contradictory results (9,10). To improve the situation, knowledge of the factors underlying these 
persistent health concerns in coeliac patients is required. Thus far, only a limited number of studies 
have investigated this issue (11); data are scant, particularly in screen-detected patients and in 
subjects with extraintestinal presentation (9,12).  
 
The aim of this large nationwide study was to find predictors of persistent gastrointestinal 
symptoms and reduced health-related quality of life in long-term treated adult coeliac patients. 
Particular attention was devoted to aspects such as duration and severity of symptoms before 
diagnosis and presence of coeliac disease-associated and other co-morbidities.   
Methods 
Study design and participants 
The trial was conducted at the Department of Gastroenterology and Alimentary Tract Surgery, 
Tampere University Hospital. Adult volunteers were recruited by a nationwide search using 
newspaper advertisements and via national and local coeliac disease societies. The study cohort 
comprised a total of 596 adults (age > 18 years) with biopsy-proven coeliac disease. All coeliac 
diagnoses and other relevant medical data (see below) were confirmed from the patients’ medical 
records. Subjects who had been on a gluten-free diet less than one year, had biopsy-proven 
refractory coeliac disease, or whose coeliac disease diagnosis could not be verified were excluded 
from the study.  
 
6 
 
All eligible subjects filled self-administered, validated and structured gastrointestinal symptom and 
corresponding health-related quality of life questionnaires. Next, to reveal factors associated with 
persistent symptoms and poor quality of life, the participants were interviewed by a physician or 
study nurse with expertise in coeliac disease. They were asked to report their demographic data and 
family history of coeliac disease, clinical presentation of the condition, time and place of diagnosis 
(primary, secondary or tertiary health care), dietary counseling and regular follow-up, adherence to 
the gluten-free diet, possible consumption of oats and duration of diet. Furthermore, the presence of 
coeliac disease-associated or other significant co-morbidities such as autoimmune thyroidal disease 
or type 1 diabetes, was inquired after.  
 
Clinical presentation at diagnosis was further categorized into gastrointestinal (any kind of 
gastrointestinal symptom or signs of malabsorption), extraintestinal (e.g. dermatitis herpetiformis, 
neurological symptoms or arthralgia) and screen-detected (subjects identified by screening in at-risk 
groups).  Duration of symptoms was defined as first experienced symptom until diagnosis, and was 
divided into three subgroups as follows: no symptoms, symptoms 10 years or less and symptoms 
more than 10 years. Further, the self-perceived severity of the symptoms was asked and divided into 
three subgroups as follows:  no symptoms, moderate symptoms and severe symptoms.   
 
Altogether 110 healthy subjects (81 % females, median age 49 (range 24-87) years) having no first-
degree relatives with coeliac disease were used as a non-coeliac control group. The controls were 
recruited from the close neighborhood and among friends of the coeliac patients.  
 
All participants gave written informed consent. The study protocol was approved by the Ethical 
Committee of Tampere University Hospital. 
  
Health-related quality of life and gastrointestinal symptoms 
The current self-perceived gastrointestinal symptoms and health-related quality of life of the 
participants were evaluated by structured and well-validated questionnaires widely applied in 
coeliac disease research (7,12-15). The Gastrointestinal Symptom Rating Scale (GSRS) (16,17) was 
used to evaluate gastrointestinal symptoms. The questionnaire comprises 15 separate items covering 
five different sub-dimensions: diarrhoea, indigestion, constipation, abdominal pain and reflux. The 
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scoring is based on a 7-grade Likert scale in which 1 point indicates no symptoms and 7 points the 
most severe gastrointestinal symptoms. Values for each sub-dimension score are calculated as a 
mean of the relevant items.  The total GSRS score is calculated as a mean value of all 15 items and 
may thus also gain values between 1 to 7 points. Patients with a score higher than 1 standard 
deviation (SD, 0.66 points) compared to the control mean were considered to have increased 
gastrointestinal symptoms (18-20). The threshold score for increased symptoms was therefore 2.55 
points.  
 
The Psychological General Well-Being (PGWB) questionnaire (12,13,15,21) was used to measure 
health-related quality of life. This survey consists of 22 separate items covering six different sub-
dimensions: anxiety, depression, well-being, self-control, general health and vitality. The scoring is 
based on a 6-grade Likert scale in which higher scores indicate better quality of life. The value of 
the total PGWB score may range from a minimum of 22 to maximum 132. The sub-scores are 
calculated as a sum of the items in each sub-dimension in question. Subjects with a score less than 1 
SD (12.1 points) compared to the control mean were considered to have reduced quality of life (18-
20), so the threshold score was 93.1 points.  
            
Adherence to the gluten-free diet 
The possible consumption of gluten-containing products was assessed by a combination of self-
reported adherence and coeliac disease serology. Participants were rated strictly adherent if they 
reported being on a strict gluten-free diet in dietary interview and were found to be negative for 
serum endomysial (EmA) and transglutaminase 2 (TG2-ab) antibodies.  
 
Serum IgA class EmA were measured by an indirect immunofluorescence method with human 
umbilical cord as substrate (22) and serum IgA class TG2-ab by enzyme-linked immunosorbent 
assay (QUANTA Lite h-tTG IgA, INOVA Diagnostics, San Diego, CA, USA). A dilution of 1: 5 
for EmA was considered positive and positive samples were further diluted 1:50, 1:100, 1:200, 
1:500, 1:1000, 1:2000 and 1:4000. In TG2-ab unit values 30 U/I were considered positive. In cases 
known to involve selective IgA deficiency, the corresponding IgG-class antibodies were applied.  
 
Statistics 
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Categorical data were described using percentages and quantitative data using medians with range. 
Binary logistic regression analysis was used to identify factors associated with reduced quality of 
life. Results are presented as odds ratios (OR) with 95% confidence intervals (CI). A p-value  0.05 
was considered statistically significant. T-test was used to compare the GSRS and PGWB mean 
scores between coeliac patients and healthy controls. 
 
If a patient failed to answer on one or two items in the PGWB or GSRS questionnaire, the missing 
answer was replaced by the mean value of the other scores for the same subject. If more than two 
answers were missing the questionnaire was disqualified. All statistical data were analyzed by the 
Predictive Analytic SoftWare for Windows version 19 (IBM Corporation, Armonk, NY, USA). 
Results  
Clinical characteristics of the study cohort are shown in Table 1. In total, 69% of the subjects were 
diagnosed on the basis of classical gastrointestinal presentation and 31% on the basis of 
extraintestinal symptoms or by screening in at-risk coeliac disease groups. Altogether 88% of the 
subjects were strictly adherent; none reported totally unrestricted gluten consumption and 82% used 
oats as a regular part of their diet. Lactose intolerance was present in 17 %, food allergy in 5% and 
fructose intolerance in none of the participants. Further, 6% of the subjects had reflux disease, 4 % 
gastritis, 2% diverticulosis and 2% cholelithiasis. The most common psychiatric disorder was 
depression, with a prevalence of 2 % (78 % of subjects with psychiatric diagnosis). 
 
The mean total GSRS score was 2.1 (range 1.0- 4.8) in the study group and 1.9 (range 1.0- 4.2) in 
the controls. The score was higher than 1 SD compared to the control mean in 25% of the 
participants. There was no significant association between the persistent gastrointestinal symptoms 
and gender or current age, but patients diagnosed between the age of 25 and 60 years had more 
persistent symptoms than those diagnosed at younger or older age (Table 2). Further, subjects who 
had suffered from moderate or severe symptoms at the time of the diagnosis or had had symptoms 
more than 10 years before it had more current gastrointestinal symptoms than initially 
asymptomatic patients. Patients diagnosed on extraintestinal symptoms had fewer current symptoms 
than those with gastrointestinal presentation (Table 2). The presence of thyroid disease, non-coeliac 
food intolerance, other gastrointestinal disease and any coeliac disease-related co-morbidity also 
increased the risk of persistent symptoms. None of the other variables examined, including dietary 
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non-adherence and consumption of oats, was associated with persistent symptoms. The GSRS mean 
total score was significantly higher in the study participants than in control subjects (p= 0.003). 
 
The mean PGWB total score was 102.8 (range 29.0-132.0) in the study group and 105.3 (range 
65.0-126.0) in the controls. Altogether 25% of the participants had the score lower than 1 SD 
compared to the control mean. Reduced health-related quality of life was seen in patients with 
manifest symptoms prior to diagnosis compared with asymptomatic subjects; the difference was 
evident in particular among those with symptoms for more than 10 years. Further, subjects with any 
psychiatric co-morbidity had reduced quality of life (Table 3). A similar trend was observed in 
patients with neurological disease and gastrointestinal co-morbidity, but the results in question were 
not statistically significant (Table 3). Of note, patients with persistent gastrointestinal symptoms 
were also more likely to have reduced quality of life (OR 4.66, CI 3.01-7.00, p < 0.001). The 
coeliac patients had lower mean PGWB scores than healthy subjects (p = 0.05).  
Discussion  
The results of our nationwide study showed that up to 25 % of adult coeliac disease patients suffer 
from persistent gastrointestinal symptoms despite a strict gluten-free diet. These findings show an 
excess of gastrointestinal complaints in treated coeliac patients, although to a somewhat lesser 
extent than noted in some previous studies (23,24). Yet it needs to be remembered that comparison 
between studies is difficult because both the methods to measure and definitions used for persistent 
symptoms may differ. Further, it is important to distinguish primary non-responsive patients from 
those investigated in the present study; common reasons for non-responsive coeliac disease are 
inadvertent gluten intake, refractory coeliac disease and concomitant diseases such as malignancies, 
microscopic colitis and pancreatic insufficiency (5,25,26). Patients with any such concomitant 
condition or refractory coeliac disease were excluded from the present study. Furthermore, although 
no histological evaluation was undertaken here, judging from both dietary interview and serological 
testing the majority of participants were adhering strictly to the diet. It would thus seem unlikely 
that inadvertent gluten intake or presence of the aforesaid adjunct disease would explain the 
ongoing gastrointestinal symptoms.  
 
In the present study, coeliac patients diagnosed at working age had more current symptoms than 
those diagnosed at an either younger or older age. Although we cannot confirm the reason for this 
age dependency of the symptoms, it is possible that changes in established dietary habits are more 
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difficult to cope with simultaneously with other challenges encountered in daily work and family 
life. Likewise, for some unexplained reason, irritable bowel syndrome (IBS) often emerges in early 
adulthood (27). Interestingly, also severe and long-lasting symptoms prior to diagnosis predispose 
coeliac patients to persistent symptoms. It has been suggested that such long-lasting abdominal 
complaints result in a chronic cycle of pain in consequence of changes in the gut-brain axis (28,29). 
Of note, similar chronic alterations have been hypothesized to be involved in the pathogenesis of 
IBS, which often co-exists with coeliac disease (30-32). There is also evidence suggesting that the 
symptoms in IBS might be caused by continuous low-grade small-bowel mucosal inflammation 
(30,31,33), a condition which may persist in coeliac disease despite a strict gluten-free diet (34,35). 
Finally, small-intestinal bacterial overgrowth may account for symptoms in both coeliac disease and 
IBS and is also accompanied by mucosal inflammation (33,36,37). Whatever mechanisms lie 
behind the persistent symptoms, our results indicate that they could be ameliorated by diagnosing 
coeliac disease as early as possible. 
 
The results obtained showed the presence of a coeliac disease-related co-morbidity, another 
gastrointestinal disorder or non-coeliac food intolerance to predispose to persistent symptoms. It is 
possible that concomitant gastrointestinal co-morbidity further reinforces the impact of the 
aforementioned long-lasting changes in the gut-brain axis. Interestingly, a particular association was 
seen between persistent symptoms and concomitant thyroid disease, which when untreated is 
known to may cause abdominal complaints, these usually recovering on treatment (38). However, 
some patients evince persistent clinical symptoms and reduced health-related quality of life even 
while on treatment and euthyroid (39). The pathogenic mechanisms underlying this remain unclear, 
but clearly the possible connection between thyroid disease and persistent gastrointestinal 
symptoms in coeliac disease calls for further investigation.  
 
As was the case with gastrointestinal symptoms, a substantial proportion of the coeliac patients here 
showed reduced health-related quality of life while on a gluten-free diet. Again, long duration of 
symptoms before diagnosis was a predisposing factor. In contrast, there was no association between 
clinical manifestations of coeliac disease at diagnosis and current quality of life. This is in line with 
our previous results showing similar health-related quality of life in screen-detected and symptom-
detected coeliac patients on a gluten-free diet (12,13). These findings constitute further evidence 
that early detection and dietary treatment of coeliac disease is beneficial even in screen-detected 
patients with mild or atypical symptoms at diagnosis.  
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There was a significant association between reduced quality of life and the presence of psychiatric 
co-morbidities in our study patients. This is in accord with some previous findings and there is also 
evidence that such coeliac patients might benefit from intensified psychological counseling 
(8,18,40-42). Consequently, health-care professionals should pay particular attention to this patient 
group, who may need special support with their dietary treatment (42). Since in the present study 
78% of participants with a psychiatric disorder suffered from depression, the role of other 
psychiatric disorders needs further investigation. Although not statistically significant, there was a 
trend suggesting that the presence of certain other co-morbidities, for example neurological 
disorders, other gastrointestinal diseases or non-coeliac food intolerance are factors predisposing to 
reduced quality of life in coeliac disease. Further studies are warranted to clarify the significance of 
these issues.  
 
A major strength of our study was a large study cohort with well-defined coeliac disease diagnoses 
and clinical data. In addition, there were a substantial number of screen-detected patients and 
subjects with extraintestinal presentation of coeliac disease. A possible limitation, on the other 
hand, was that a substantial proportion of the participants were recruited through local or national 
coeliac disease associations, which might have caused some selection bias. Furthermore, our 
participants showed excellent adherence to the gluten-free diet, this however being in accord with 
our earlier findings (12). Although good adherence is beneficial for the patient, in this study it might 
have concealed the association between poor adherence and reduced quality of life. As a 
consequence, results may be different in countries where adherence to a gluten-free diet is lower. 
Although the threshold value of 1 SD to define increased symptoms and reduced quality of life has 
also been used in other studies, it is somewhat artificial. The fact that healthy controls were not 
precisely matched with the study participants was also a limitation. 
 
The majority of participants used oats as a regular part of their diet, and this was not associated with 
increased gastrointestinal symptoms or reduced quality of life. This is important, since the use of 
oat-containing products in coeliac disease has hitherto remained controversial (43). Based on our 
previous results (44) and the findings here, purified oats could be a regular part of a gluten-free diet. 
One important issue which should be considered in evaluating gastrointestinal symptoms in coeliac 
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patients is that commercial gluten-free products may have marked qualitative differences, for 
example in the use of additives and preservatives and the amount of fibre (45). 
Conclusions  
As a conclusion, we showed that many coeliac disease patients suffer from persistent 
gastrointestinal symptoms and reduced quality of life despite strict dietary treatment. In particular, 
long-lasting and severe symptoms before the diagnosis and concomitant thyroid, gastrointestinal 
and psychiatric co-morbidities were significant risk factors for these ongoing health concerns. The 
results emphasize the importance of early diagnosis and careful follow-up in coeliac disease. 
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Table 1. Demographic data and clinical characteristics of the 596 
coeliac disease patients. 
Female, n (%) 452 (76) 
Current age, median (range), years 55 (19-92) 
Age at diagnosis, median (range), years 44 (1-82) 
Site of diagnosis, n (%)  
Primary care 149 (25) 
Secondary or tertiary care 446 (75) 
Presenting symptom at time of diagnosis, n (%)  
Gastrointestinal 1 410 (69) 
Extraintestinal 2 95 (16) 
Screen-detected 3 91 (15) 
Coeliac disease in family, n (%) 372 (62) 
Coeliac disease-associated disorders, n (%)  
Type 1 diabetes mellitus  14 (2) 
Thyroid disease  107 (18) 
Gluten-free diet, n (%)  
Strict 520 (88) 
Occasional gluten 76 (12) 
No diet 0 
Consumption of oats, n (%) 487 (82) 
Duration of gluten-free diet, median (range), years 10 (1-53) 
  1Stomach pain, diarrhoea, constipation, heartburn, flatulence, 
swelling, anaemia, malabsorption 
2 Dermatitis herpetiformis, tiredness, joint pains, neurologic 
symptoms, gynaecologic problems 
3Coeliac disease in relatives, presence of autoimmune disorder 
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Table 2. Factors associated with persistent gastrointestinal symptoms* in treated coeliac disease 
patients. 
Variable  n Symptoms,% OR 95 % CI p-value 
Gender Male 144 22 1.00   Female 452 26 1.26 0.80-1.97 0.317 
Present age, years 
< 25 12 20 1.00   
25-60 380 24 1.25 0.26-6.01 0.778 
> 60 204 27 1.51 0.31-7.33 0.611 
Age at diagnosis, years 
< 25 79 13 1.00   
25-60 457 27 2.86 1.38-5.91 0.050 
> 60 60 20 1.99 0.77-5.10 0.154 
Symptoms at diagnosis 
Gastrointestinal 410 27 1.00   
Extraintestinal 95 17 0.56 0.31-1.00 0.050 
Screen-detected 91 24 0.88 0.52-1.49 0.636 
Duration of symptoms 
before diagnosis, years 
No symptoms 37 11 1.00   
 10 350 22 2.33 0.80-6.77 0.121 
> 10 182 34 4.16 1.41-12.28 0.010 
Severity of symptoms at 
diagnosis 
No symptoms 62 13 1.00   
Moderate 457 25 2.27 1.05-4.91 0.037 
Severe 77 31 3.06 1.26-7.41 0.013 
Site of diagnosis Hospital 446 25 1.00   Primary care 149 25 1.01 0.66-1.55 0.967 
Coeliac disease in 
family 
Yes 372 24 1.00   
No 224 25 1.02 0.73-1.57 0.731 
Type 1 diabetes mellitus No 582 25 1.00   Yes 14 29 1.23 0.38-3.97 0.735 
Thyroid disease No 489 22 1.00   Yes 107 36 2.02 1.29-3.16 0.002 
Malignancy No 565 25 1.00   Yes 31 26 1.04 0.47-2.43 0.884 
Psychiatric disease No 578 24 1.00   Yes 18 39 1.99 0.76-5.22 0.164 
Neurologic disease No 520 24 1.00   Yes 76 30 1.38 0.81-2.35 0.231 
Other food intolerance No 470 22 1.00   Yes 126 33 1.74 1.13-2.67 0.012 
Other gastrointestinal 
disease 
No 388 22 1.00   
Yes 208 34 1.80 1.16-2.80 0.009 
Any coeliac disease-
related co-morbidity 
No 72 14 1.00   
Yes 523 26 2.20 1.10-4.40 0.027 
Strict gluten-free diet Yes 523 24 1.00   No 73 27 1.17 0.68-2.04 0.570 
Consumption of oats No 105 25 1.00   Yes 487 23 0.87 0.54-1.41 0.568 
Duration of diet, years 
> 10 270 27 1.00   
5-10 195 23 0.80 0.51-1.25 0.326 
<5 131 25 0.92 0.57-1.42 0.730 
Professional dietary Yes 484 24 1.00   
20 
 
advice No 112 27 1.15 0.72-1.83 0.564 
Regular follow-up Yes 166 25 1.00   No 412 23 0.93 0.61-1.41 0.721 
*Defined as a score >1 standard deviation from the mean Gastrointestinal Symptom Rating 
Scale total score of healthy controls; CI, confidence interval; OR, odds ratio defined by bivariate 
logistic regression.  
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Table 3. Factors associated with persistently reduced quality of life* in treated coeliac disease 
patients.  
Variable  n Reduced, % OR 95 % CI p-value 
Gender Male 144 24 1.00   Female 452 25 1.07 0.69-1.67 0.777 
Present age, years 
< 25 12 10 1.00   
25-60 380 26 3.21 0.40-25.66 0.272 
> 60 204 21 2.40 0.30-19.51 0.413 
Age at diagnosis, years 
< 25 79 25 1.00   
25-60 457 25 0.97 0.56-1.68 0.911 
> 60 60 22 0.82 0.37-1.81 0.617 
Symptoms at diagnosis 
Gastrointestinal 410 26 1.00   
Extraintestinal 95 19 0.65 0.37-1.14 0.136 
Screen-detected 91 22 0.79 0.46-1.36 0.389 
Duration of symptoms 
before diagnosis, years 
No symptoms 37 8 1.00   
 10 350 24 3.58 1.07-11.95 0.038 
> 10 182 28 4.41 1.30-15.01 0.017 
Severity of symptoms at 
diagnosis 
No symptoms 62 18 1.00   
Moderate 457 26 1.61 0.81-3.20 0.170 
Severe 77 22 1.31 0.56-3.06 0.527 
Site of diagnosis Hospital 446 25 1.00   Primary care 149 24 0.97 0.63-1.50 0.902 
Coeliac disease in 
family 
Yes 372 25 1.00   
No 224 24 0.97 0.66-1.42 0.864 
Type 1 diabetes mellitus No 582 25 1.00   Yes 14 21 0.84 0.23-3.04 0.785 
Thyroid disease No 489 24 1.00   Yes 107 25 1.05 0.65-1.70 0.845 
Malignancy No 565 25 1.00   Yes 31 13 0.44 0.15-1.28 0.132 
Psychiatric disease No 578 23 1.00   Yes 18 67 6.63 2.44-17.99 <0.001 
Neurologic disease No 520 23 1.00   Yes 76 33 1.62 0.96-2.72 0.070 
Other food intolerance No 470 24 1.00   Yes 126 28 1.24 0.80-1.94 0.335 
Other gastrointestinal 
disease 
No 388 23 1.00   
Yes 208 32 1.56 1.00-2.45 0.052 
Any coeliac disease-
related co-morbidity 
No 72 26 1.00   
Yes 523 24 0.89 0.51-1.56 0.691 
Strict gluten-free diet Yes 523 24 1.00   No 73 27 1.19 0.69-2.07 0.539 
Consumption of oats No 105 22 1.00   Yes 487 25 1.19 0.72-1.98 0.497 
Duration of diet, years 
> 10 270 23 1.00   
5-10 195 23 0.96 0.61-1.52 0.875 
<5 131 29 1.35 0.84-2.18 0.221 
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Professional dietary 
advice 
Yes 484 24 1.00   
No 112 28 1.23 0.77-1.95 0.385 
Regular follow-up Yes 166 24 1.00   No 412 24 1.00 0.65-1.52 0.986 
*Defined as a score >1 standard deviation from the mean Psychological General Well-Being total 
score of healthy controls; CI, confidence interval; OR, odds ratio defined by bivariate logistic 
regression. 
